Nanexa AB (publ) (NANEXA.ST) Research

Nanexa AB (publ) is a firm dedicated to developing advanced drug delivery solutions through nanotechnology. The company leverages its proprietary PharmaShell platform, a nanobased system that utilizes atomic layer deposition (ALD) technology for drug administration. Furthermore, Nanexa is progressing NEX-18, a PharmaShell-based candidate specifically designed to address severe conditions such as Myelodysplastic Syndrome and Acute Myeloid Leukemia. The company was established in 2007 and is headquartered in Uppsala, Sweden.

Market snapshot

Symbol
NANEXA.ST
Price
$3.91
Day change
-8.00%
Market cap
$643.5M
P/E ratio
-39.86x
52-week range
1.4-5
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Peer companies

  • Acarix AB (publ) (ACARIX.ST)
  • AlzeCure Pharma AB (publ) (ALZCUR.ST)
  • Boule Diagnostics AB (publ) (BOUL.ST)
  • Elicera Therapeutics AB (publ) (ELIC.ST)
  • Enorama Pharma AB (publ) (ERMA.ST)
  • Mentice AB (publ) (MNTC.ST)
  • Moberg Pharma AB (publ) (MOB.ST)
  • Promimic AB (publ) (PRO.ST)

Open Nanexa AB (publ) (NANEXA.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.